Skip to main content

Table 5 Results of base case analysis

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

  Total direct medical cost ($) QALY Incremental cost ($) Incremental QALY ICER($/QALY) Ref
Monotherapy 3434.834 0.501 Ref Ref Ref
Combination therapy 8424.188 0.732 4,989.354 0.231 21,553.630 Monotherapy